Viatris Inc. (VTRS): Price and Financial Metrics

Viatris Inc. (VTRS): $9.33

0.13 (+1.41%)

POWR Rating

Component Grades














  • Value is the dimension where VTRS ranks best; there it ranks ahead of 99.48% of US stocks.
  • VTRS's strongest trending metric is Quality; it's been moving up over the last 179 days.
  • VTRS's current lowest rank is in the Momentum metric (where it is better than 6.74% of US stocks).

VTRS Stock Summary

  • VIATRIS INC's stock had its IPO on December 18, 1987, making it an older stock than 91.49% of US equities in our set.
  • In terms of twelve month growth in earnings before interest and taxes, VIATRIS INC is reporting a growth rate of -12,176.6%; that's higher than only 0.22% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for VTRS comes in at 34.3% -- higher than that of 94.67% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to VIATRIS INC are OPK, LUNA, GNSS, BZFD, and SRTS.
  • Visit VTRS's SEC page to see the company's official filings. To visit the company's web site, go to

VTRS Valuation Summary

  • VTRS's price/sales ratio is 0.7; this is 63.16% lower than that of the median Healthcare stock.
  • Over the past 243 months, VTRS's price/earnings ratio has gone down 14.7.

Below are key valuation metrics over time for VTRS.

Stock Date P/S P/B P/E EV/EBIT
VTRS 2023-03-17 0.7 0.5 5.4 8.6
VTRS 2023-03-16 0.7 0.5 5.5 8.6
VTRS 2023-03-15 0.7 0.5 5.5 8.6
VTRS 2023-03-14 0.7 0.6 5.7 8.8
VTRS 2023-03-13 0.7 0.6 5.7 8.7
VTRS 2023-03-10 0.7 0.6 5.8 8.8

VTRS Growth Metrics

    Its 5 year net cashflow from operations growth rate is now at -11.78%.
  • The 4 year cash and equivalents growth rate now stands at -20.92%.
  • Its 4 year price growth rate is now at -55.64%.
VTRS's revenue has moved up $1,124,600,000 over the prior 15 months.

The table below shows VTRS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 16,728.3 3,333.1 803.6
2022-06-30 17,186.7 3,549.7 760.8
2022-03-31 17,647.7 3,306.6 167.7
2021-12-31 17,886.3 3,016.9 -1,269.1
2021-09-30 17,168.2 2,530 -1,921.1
2021-06-30 15,603.7 1,969.4 -2,046.9

VTRS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VTRS has a Quality Grade of D, ranking ahead of 8.02% of graded US stocks.
  • VTRS's asset turnover comes in at 0.298 -- ranking 155th of 682 Pharmaceutical Products stocks.
  • CRIS, KDNY, and AGIO are the stocks whose asset turnover ratios are most correlated with VTRS.

The table below shows VTRS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.298 0.277 -0.030
2021-03-31 0.302 0.292 -0.027
2020-12-31 0.312 0.318 -0.011
2020-09-30 0.375 0.363 0.058
2020-06-30 0.375 0.356 0.052
2020-03-31 0.374 0.344 0.047

VTRS Price Target

For more insight on analysts targets of VTRS, see our VTRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.21 Average Broker Recommendation 1.72 (Moderate Buy)

VTRS Stock Price Chart Interactive Chart >

Price chart for VTRS

VTRS Price/Volume Stats

Current price $9.33 52-week high $12.40
Prev. close $9.20 52-week low $8.42
Day low $9.08 Volume 7,014,700
Day high $9.36 Avg. volume 9,562,725
50-day MA $11.14 Dividend yield 5.22%
200-day MA $10.51 Market Cap 11.17B

Viatris Inc. (VTRS) Company Bio

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania. The company was formed through the merger of Mylan and Upjohn, a division of Pfizer, on November 16, 2020. (Source:Wikipedia)

VTRS Latest News Stream

Event/Time News Detail
Loading, please wait...

VTRS Latest Social Stream

Loading social stream, please wait...

View Full VTRS Social Stream

Latest VTRS News From Around the Web

Below are the latest news stories about VIATRIS INC that investors may wish to consider to help them evaluate VTRS as an investment opportunity.

3 Healthcare Spinoffs Worth a Look, But 1 Has the Best Long-Term Potential

Healthcare spinoffs aren't normally seen as companies with strong growth potential. More likely than not, spinoffs stem from a division of a company that, while possibly profitable, is seeing slower growth. Embecta (NASDAQ: EMBC.V), Viatris (NASDAQ: VTRS) and GE Healthcare Technologies (NASDAQ: GEHC) are three of the bigger healthcare spinoffs in recent years.

Yahoo | March 26, 2023

I Own 12 High-Yield Dividend Stocks. Here's the Best of the Bunch.

How high of a dividend yield does a stock need to have to be considered a high-yield stock? Opinions vary. However, many investors would include any stock with a yield that's greater than that offered by 10-year U.

Yahoo | March 25, 2023

Pfizer Has Another Blockbuster on the Horizon, but That's Not All

Over the past year, Pfizer (NYSE: PFE) made a series of acquisitions, even announcing at one point that it planned to remain "very active in deal-making." On March 13, Pfizer announced the planned blockbuster acquisition of cancer specialist Seagen (NASDAQ: SGEN) for a massive $43 billion in cash. This move, expected to close by year-end or early 2024, will likely improve Pfizer's prospects, and it is only the latest in a series of important and successful strategic decisions the company's management has made.

Yahoo | March 21, 2023

Is Viatris' 5% Dividend Yield Safe?

Viatris (NASDAQ: VTRS) makes both generic and branded drugs and its stock looks like a potential steal of a deal at the moment. Holding a lot of debt as interest rates are rising can be risky, and that's likely why investors are extra cautious when it comes to Viatris. Interest expenses of $592.4 million in 2022 were 7% lower than the $636.2 million that Viatris incurred a year earlier.

Yahoo | March 21, 2023

Nasdaq Bear Market: These 3 Stocks Are Trading Below Their Book Values

The collapse of SVB Financial's Silicon Valley Bank last week likely threw a monkey wrench into the macroeconomic machinery that was working to end the current bear market. Three Nasdaq stocks that look like potential bargains and that investors don't even have to pay book value for right now are Viatris (NASDAQ: VTRS), Warner Bros. Discovery (NASDAQ: WBD), and Kraft Heinz (NASDAQ: KHC). Generic and branded drugmaker Viatris has consistently been trading below its book value over the past year.

Yahoo | March 14, 2023

Read More 'VTRS' Stories Here

VTRS Price Returns

1-mo -18.02%
3-mo -14.53%
6-mo 9.26%
1-year -12.87%
3-year N/A
5-year N/A
YTD -15.22%
2022 -14.29%
2021 -26.12%
2020 N/A
2019 N/A
2018 N/A

VTRS Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full VTRS Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7552 seconds.